MCID: GST037
MIFTS: 52

Gastroparesis

Categories: Gastrointestinal diseases, Metabolic diseases, Muscle diseases, Rare diseases

Aliases & Classifications for Gastroparesis

MalaCards integrated aliases for Gastroparesis:

Name: Gastroparesis 12 20 54 44 15 17 71
Delayed Gastric Emptying 20
Gastroparesis Syndrome 12
Gastroparalysis 12
Gastric Atonia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11914
ICD9CM 34 536.3
MeSH 44 D018589
NCIt 50 C80512
SNOMED-CT 67 235675006
ICD10 32 K31.84
UMLS 71 C0152020

Summaries for Gastroparesis

GARD : 20 Gastroparesis, or delayed gastric emptying, is a disorder where the food does not move or moves very slowly from the stomach to the small intestine. In gastroparesis, the muscles of the stomach do not work well and digestion takes an abnormally long time. Symptoms of gastroparesis include bloating, nausea, vomiting, weight loss due to poor absorption of nutrients, early fullness while eating meals, heartburn, and abdominal pain. Complications can occur including dehydration, electrolyte abnormalities, blood sugar abnormalities, malnutrition, vitamin deficiencies, stomach ulcers, gastroesophageal reflux, esophagitis, small bowel bacterial overgrowth, and metabolic bone disease. In rare cases, food that is poorly digested can collect in the stomach and form a bezoar, a mass of undigested material that can cause a blockage in the gastrointestinal tract. Gastroparesis is more common in people with diabetes and those who have had recent stomach or intestinal surgery. Other causes include infections, hormonal disorders like hypothyroidism, connective tissue disorders like scleroderma, autoimmune conditions, neuromuscular diseases, psychological conditions, and eating disorders. In some cases, the cause is not known (idiopathic). Diagnosis is made on the basis of a radiographic gastric emptying test. Treatment may include dietary modifications such as adjusting the timing and size of meals, consuming more liquid-based meals, or avoiding foods that are more difficult to digest (such as fatty foods, or foods with too much fiber). Other treatments may include endoscopic procedures to break the bezoar apart and remove it, feeding tubes, surgery, placement of an electrical stimulator, and medication such as metoclopramide, domperidone, erythromycin and cisapride. With proper management many people with gastroparesis can live a relatively normal life. However, others may not tolerate treatment and may experience significant complications, a decreased quality of life, and reduced survival.

MalaCards based summary : Gastroparesis, also known as delayed gastric emptying, is related to idiopathic gastroparesis and autonomic neuropathy, and has symptoms including ophthalmoplegia, hemiplegia and signs and symptoms, digestive. An important gene associated with Gastroparesis is MLN (Motilin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Glucose / Energy Metabolism. The drugs Sodium citrate and Esomeprazole have been mentioned in the context of this disorder. Affiliated tissues include small intestine, smooth muscle and kidney, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Gastroparesis (gastro- from Ancient Greek γαστήρ - gaster, "stomach"; and -paresis, πάρεσις - "partial... more...

Related Diseases for Gastroparesis

Diseases related to Gastroparesis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 400)
# Related Disease Score Top Affiliating Genes
1 idiopathic gastroparesis 31.5 MRC1 HMOX1 GIP GHSR GHRL
2 autonomic neuropathy 31.2 MLN GAST CCK
3 gastroesophageal reflux 30.7 MLN GHRL GAST CCK
4 pylorospasm 30.7 MLNR MLN
5 diabetic autonomic neuropathy 30.7 MLNR MLN GAST
6 tardive dyskinesia 30.6 DRD2 CYP2D6
7 rumination disorder 30.6 MLNR MLN
8 eating disorder 30.3 GHRL DRD2 CCK
9 bulimia nervosa 30.3 GHRL DRD2 CCK
10 intestinal pseudo-obstruction 30.2 SST MLNR MLN
11 volvulus of midgut 30.2 SST MLNR MLN
12 gastritis 30.1 SST SCT GHRL GAST
13 irritable bowel syndrome 30.1 SST MLN GHRL CCK
14 gastrointestinal system disease 30.1 MLN GHRL GAST CCK
15 atrophic gastritis 30.0 SST GHRL GAST
16 hernia, hiatus 29.9 MLN GHRL GAST
17 hyperglycemia 29.9 SST GIP GHRL CCK
18 peptic esophagitis 29.9 MLN GAST
19 bile reflux 29.9 SCT MLN GAST CCK
20 pyloric stenosis 29.8 SST NOS1 MLN GAST
21 biliary dyskinesia 29.8 SST SCT CCK
22 alcohol dependence 29.7 TH GHRL DRD2 CCK
23 small cell cancer of the lung 29.7 SST GAST CCK
24 peptic ulcer disease 29.6 SST SCT GHRL GAST
25 gallbladder disease 29.6 SST MLN CCK
26 cholelithiasis 29.5 SST GAST CCK
27 celiac disease 1 29.5 SCT GHRL GAST CCK
28 ileus 29.5 SST MLN GHSR GHRL CCK
29 sexual disorder 29.4 NOS1 CYP3A4 CYP2D6
30 duodenal ulcer 29.3 SST SCT MLN GAST CCK
31 duodenogastric reflux 29.1 SST SCT MLN GAST CCK
32 migraine with or without aura 1 29.0 SCT NOS1 DRD2 CYP3A4 CYP2D6 CCK
33 dumping syndrome 29.0 SST SCT MLN GIP GHRL GAST
34 acute pancreatitis 29.0 SST SCT CCK
35 anxiety 28.9 TH GHRL DRD2 CYP3A4 CYP2D6 CCK
36 diarrhea 28.7 SST SCT MLN GAST CYP3A4 CYP2D6
37 constipation 28.5 TH SST NOS1 MLNR MLN GHRL
38 body mass index quantitative trait locus 11 28.0 NOS1 MLN KCNH2 HMOX1 GIP GHSR
39 type 2 diabetes mellitus 28.0 SST SCT NOS1 HMOX1 GIP GHRL
40 diabetes mellitus 27.2 TH SST SCT NOS1 MLN HMOX1
41 brittle diabetes 11.0
42 stomach disease 11.0
43 galactorrhea 10.4 DRD2 CYP2D6
44 neurogenic bowel 10.4 MLN GAST
45 acute diffuse nephritis 10.3 KCNH2 ABCB1
46 type 1 diabetes mellitus 10.3
47 postcholecystectomy syndrome 10.3 MLN GAST CCK
48 neuropathy 10.3
49 dysphagia 10.3
50 opioid addiction 10.3 DRD2 CCK ABCB1

Graphical network of the top 20 diseases related to Gastroparesis:



Diseases related to Gastroparesis

Symptoms & Phenotypes for Gastroparesis

UMLS symptoms related to Gastroparesis:


ophthalmoplegia, hemiplegia, signs and symptoms, digestive, lassitude, persistent vomiting

GenomeRNAi Phenotypes related to Gastroparesis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.68 SST
2 Decreased viability GR00249-S 9.68 ABCB1 ANO1 GHRL GHSR MLN NOS1
3 Decreased viability GR00381-A-1 9.68 CYP2D6 GHSR MLN MLNR SCT
4 Decreased viability GR00381-A-2 9.68 GHSR
5 Decreased viability GR00381-A-3 9.68 GHSR MLN
6 Decreased viability GR00386-A-1 9.68 CCK MLN
7 Decreased viability GR00402-S-2 9.68 ABCB1 ADRA1D CYP2D6 GHSR MLN SCT

MGI Mouse Phenotypes related to Gastroparesis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.81 ABCB1 ANO1 DRD2 GAST GHRL GHSR
2 homeostasis/metabolism MP:0005376 9.8 ABCB1 ANO1 CCK DRD2 GAST GHRL
3 no phenotypic analysis MP:0003012 9.17 ABCB1 CCK DRD2 GHSR NOS1 SST

Drugs & Therapeutics for Gastroparesis

Drugs for Gastroparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium citrate Approved, Investigational Phase 4 68-04-2
2
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
3
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
4
Haloperidol Approved Phase 4 52-86-8 3559
5
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
6 Mosapride Investigational Phase 4 112885-41-3
7 Citrate Phase 4
8 Proton Pump Inhibitors Phase 4
9 Anti-Ulcer Agents Phase 4
10 Antacids Phase 4
11 Serotonin Receptor Agonists Phase 4
12 Psychotropic Drugs Phase 4
13 Haloperidol decanoate Phase 4
14 Analgesics Phase 4
15 Opiate Alkaloids Phase 4
16 Antipsychotic Agents Phase 4
17
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
18
Prucalopride Approved Phase 2, Phase 3 179474-81-8
19
Nortriptyline Approved Phase 3 72-69-5 4543
20
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
21
Domperidone Approved, Investigational, Vet_approved Phase 3 57808-66-9 3151
22 Cholinergic Agents Phase 3
23 Antidepressive Agents Phase 3
24 Antidepressive Agents, Tricyclic Phase 3
25 Adrenergic Agents Phase 3
26 Neurotransmitter Agents Phase 3
27 Antiemetics Phase 3
28 Dopamine Agents Phase 3
29 Dopamine Antagonists Phase 3
30
Lixisenatide Approved Phase 1, Phase 2 320367-13-3
31
Fosaprepitant Approved Phase 2 172673-20-0 219090
32
Aprepitant Approved, Investigational Phase 2 170729-80-3 151165 6918365
33
Levodopa Approved Phase 2 59-92-7 6047
34
Buspirone Approved, Investigational Phase 2 36505-84-7 2477
35
Rifaximin Approved, Investigational Phase 2 80621-81-4 6436173 46783403
36
Erythromycin Approved, Investigational, Vet_approved Phase 2 114-07-8 12560
37
Azithromycin Approved Phase 2 83905-01-5 55185 447043
38
Metoclopramide Approved, Investigational Phase 2 364-62-5 4168
39
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
40
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
41
Promethazine Approved, Investigational Phase 2 60-87-7 4927
42
Loperamide Approved Phase 2 53179-11-6 3955
43
Bismuth subsalicylate Approved, Vet_approved Phase 2 14882-18-9 53629521
44
Methylnaltrexone Approved Phase 2 916055-93-1, 83387-25-1 6603824
45
Acetaminophen Approved Phase 2 103-90-2 1983
46
Aspartic acid Approved, Nutraceutical Phase 2 56-84-8 5960
47
gastric inhibitory polypeptide Investigational Phase 2 100040-31-1
48
Maleic acid Experimental Phase 2 110-16-7 444266
49
Metopimazine Experimental Phase 2 14008-44-7
50 Hormones Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 218)
# Name Status NCT ID Phase Drugs
1 Prucalopride Versus Placebo in Functional Dyspepsia With Delayed Gastric Emptying Unknown status NCT02510976 Phase 4 prucalopride;placebo
2 Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis Unknown status NCT02264587 Phase 4 Mosapride;domperidone
3 Effect of Proton Pump Inhibitor on Gastric Emptying and Satiety Function in Patients With Functional Dyspepsia Completed NCT00951431 Phase 4 Esomeprazole;Placebo
4 Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Patients With Heartburn Associated With Gastroparesis Completed NCT00492622 Phase 4 Immediate-release omeprazole;Delayed-release omeprazole
5 Enterra Therapy Gastric Stimulation System Terminated NCT00556166 Phase 4
6 Haloperidol vs Conventional Therapy for Gastroparesis Terminated NCT02057549 Phase 4 Haloperidol;Conventional Therapy
7 Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of R051619 (Cisapride 10 mg Q.I.D.) Versus Placebo for the Improvement of Symptoms Associated With Exacerbations of Gastroparesis, After Failure of Other Treatments, in Patients With Diabetes Mellitus Terminated NCT01286090 Phase 4 Cisapride;Placebo
8 Double-Blind, Randomized, Placebo-Controlled Trial To Assess Efficacy And Safety Of R051619 (Cisapride 10 mg q.i.d.) Versus Placebo For The Improvement Of Symptoms Associated With Exacerbations Of Idiopathic Gastroparesis, After Failure Of Other Treatment Options Terminated NCT01281540 Phase 4 Cisapride;Placebo
9 An Open-label Pilot Trial to Assess the Effect of Tegaserod on Improvement of Gastric Emptying in Patients With Diabetic Gastroparesis and Upper Gastrointestinal Symptoms Terminated NCT00390975 Phase 4 Tegaserod
10 Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis Withdrawn NCT01326117 Phase 4 tadalafil
11 A Randomized Controlled Trial of Gastric Meal With and Without Prior Jejunal Feeding on GI Symptoms and Response in Patients With Diabetic Gastro-enteropathy, Diabetic Controls and Healthy Volunteers Withdrawn NCT00944593 Phase 4
12 Effect of Electroacupuncture in Diabetic Patients With Gastroparesis Unknown status NCT00227383 Phase 3
13 Comparison Between Antecolic and Retrocolic Gastrointestinal Reconstruction in Delayed Gastric Emptying After Pancreaticoduodenectomy: A Prospective Randomized Controlled Multicenter Trial Unknown status NCT01460550 Phase 3
14 Sancuso® in Patients With Nausea and/or Vomiting From Gastroparesis: An Open Label Study. Unknown status NCT01989221 Phase 3 Sancuso®
15 Per-oral Endoscopy Pyloromyotomy (G-POEM) in the Treatment of Refractory Diabetic Gastroparesis : Prospective Evaluation of Efficacy Unknown status NCT02927886 Phase 3
16 Prucalopride Versus Placebo in Gastroparesis: Randomized Placebo-controlled Crossover Trial Completed NCT02031081 Phase 2, Phase 3 Prucalopride;Placebo
17 Double-Blind Placebo-Controlled Cross-Over Design With Wash-Out for Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis Completed NCT00432835 Phase 3
18 Phase 3 Companion Study of Intranasal Metoclopramide in Men With Symptomatic Diabetic Gastroparesis Completed NCT02025751 Phase 3 Metoclopramide Nasal Spray;Placebo Nasal Spray
19 Phase 3 Study of Intranasal Metoclopramide in Women With Symptomatic Diabetic Gastroparesis Completed NCT02025725 Phase 3 Metoclopramide Nasal Spray;Placebo Nasal Spray
20 Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG) Completed NCT00765895 Phase 3 Nortriptyline Hydrochloride;Placebo (for nortriptyline)
21 VP-VLY-686-3301: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Iii Study To Assess The Efficacy Of Tradipitant In Relieving Symptoms Of Gastroparesis Recruiting NCT04028492 Phase 3 Tradipitant;Placebo
22 Treatment Protocol for the Compassionate Use of Domperidone Recruiting NCT01696734 Phase 3 Domperidone
23 A Randomized, Placebo/Sham-Controlled, Double-Blind Crossover Study to Assess the Efficacy of Acupuncture in the Treatment of Diabetic Gastroparesis. Suspended NCT00470795 Phase 3
24 A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Terminated NCT03426345 Phase 3 Relamorelin;Placebo
25 A 46-week, Double-blind, Placebo-controlled, Phase 3 Study With a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Terminated NCT03420781 Phase 3 Relamorelin;Placebo
26 Open-label Extension Study of Relamorelin for the Treatment of Diabetic Gastroparesis Terminated NCT03786380 Phase 3 Relamorelin 10 μg
27 A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Terminated NCT03285308 Phase 3 Relamorelin;Placebo
28 A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Terminated NCT03383146 Phase 3 Relamorelin;Placebo
29 Monitoring Study for the Use of Gastroparesis for Patient Who Have Failed Standard Therapy Withdrawn NCT01378884 Phase 3 Domperidone
30 Phase III Study on Comparison for Bile Reflux and Gastric Stasis in Patients With Gastric Cancer After Distal Gastrectomy Withdrawn NCT00622804 Phase 3
31 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Efficacy of VLY-686 (Tradipitant) in Relieving Symptoms of Gastroparesis Unknown status NCT02970968 Phase 2 VLY-686 (Tradipitant)
32 Effects of Lixisenatide on Gastric Emptying, Glycaemia and 'Postprandial' Blood Pressure in Type 2 Diabetes and Healthy Subjects. Unknown status NCT02308254 Phase 1, Phase 2 Lixisenatide;Placebo
33 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of Once-Daily Administrations of TZP-102 for the Treatment of Symptoms Associated With Diabetic Gastroparesis Completed NCT01452815 Phase 2 Placebo;10mg TZP-102;20mg TZP-102
34 Acupuncture Treatment for Gastroparesis: a Pilot Study Completed NCT01643577 Phase 1, Phase 2
35 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Evaluation of the Safety and Efficacy of Once-Daily Administrations of TZP 102 for the Treatment of Symptomatic Gastroparesis in Patients With Diabetes Mellitus Completed NCT00889486 Phase 2 TZP-102;Placebo
36 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-ranging Study to Assess the Efficacy and Safety of TZP-101 When Administered as a 30 Minute I.V. Infusion to Subjects With Severe Gastroparesis Due to Diabetes Mellitus Completed NCT00612014 Phase 2 5% dextrose in water;TZP-101;TZP-101;TZP-101;TZP-101;TZP-101
37 A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis Completed NCT01262898 Phase 2 GSK962040 (5 mg tablet);GSK962040 (25 mg tablet);GSK962040 (125 mg tablet);Placebo
38 Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial Completed NCT01149369 Phase 2 Aprepitant;Placebo
39 A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis Completed NCT02210000 Phase 2 Placebo;Camicinal
40 A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying Completed NCT01602549 Phase 2 GSK962040 (25 mg tablet);Placebo
41 A Multi-center, Open-label Comparison Study of a 13C-uracil Breath Test Versus 99mTechnetium Sulfur Colloid Gastric Emptying Scintigraphy to Evaluate Normal, and Delayed Gastric Emptying Time in Dyspeptic Subjects Completed NCT01677338 Phase 2 13C-uracil;99mTc sulfur colloid
42 Pectin Start Early Enteral Nutritional Support in Critically Ill Patients Completed NCT02379624 Phase 1, Phase 2 pectin
43 A 2-Part, Randomized, Double Blind and Open-Label, Placebo and Active-Comparator Controlled Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics for TAK-906 in Subjects With Diabetes Mellitus and Gastroparesis or With Idiopathic Gastroparesis Completed NCT03268941 Phase 2 TAK-906 Maleate;Metaclopramide;TAK-906 Maleate Placebo
44 Comparing Treatment With Food of Small Particle Size and Food of Large Particle Size in Subjects With Diabetic Gastroparesis. Evaluation of Diagnostic Methods. Determination of the Motility of Gastric Emptying After Intervention Completed NCT01557296 Phase 2
45 Study Evaluating the Effect of TC-6499 on Gastric Emptying Time in Diabetic Subjects With Gastroparesis Completed NCT02187094 Phase 1, Phase 2 TC-6499;Placebo
46 A 12-Week Study Conducted at Multiple Centers, Blinded to Both the Patient and Doctor, Evaluating for Safety and Effectiveness Two Dosages of an Investigational Agent (GM-611) Versus a Placebo, That Are Randomly Assigned to Patients With Diabetic Gastroparesis Completed NCT00050882 Phase 2 GM-611
47 A Randomized, Double-Blind, Placebo-Controlled, Parallel Study of IC351 (LY450190) in Patients With Diabetic Gastroparesis Completed NCT00050609 Phase 2 tadalafil;tadalafil;placebo
48 A Pilot Study of Hemin Therapy for Gastroparesis Completed NCT01206582 Phase 2
49 A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis Completed NCT02357420 Phase 2 Relamorelin;Placebo
50 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis Completed NCT02267525 Phase 2 Velusetrag;Placebo

Search NIH Clinical Center for Gastroparesis

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Cisapride
Metoclopramide
Metoclopramide Hydrochloride

Cochrane evidence based reviews: gastroparesis

Genetic Tests for Gastroparesis

Anatomical Context for Gastroparesis

MalaCards organs/tissues related to Gastroparesis:

40
Small Intestine, Smooth Muscle, Kidney, Pancreas, Brain, Spinal Cord, Colon

Publications for Gastroparesis

Articles related to Gastroparesis:

(show top 50) (show all 2671)
# Title Authors PMID Year
1
Gastroparesis: Quality of Life and Health Care Utilization. 61 20
27775961 2018
2
Psychological controversies in gastroparesis: A systematic review. 61 20
28275310 2017
3
Gastroparesis: A Review of Current Diagnosis and Treatment Options. 61 20
25874755 2015
4
Gastroparesis: approach, diagnostic evaluation, and management. 61 20
21329779 2011
5
Ghrelin and obestatin levels in type 2 diabetic patients with and without delayed gastric emptying. 54 61
19082715 2009
6
Postprandial secretion of ghrelin in hemodialysis patients with and without diabetic nephropathy. 61 54
19776684 2009
7
Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. 61 54
19434096 2009
8
Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. 54 61
19298585 2009
9
Influence of ghrelin on the gastric accommodation reflex and on meal-induced satiety in man. 61 54
19210631 2009
10
No ghrelin response to oral glucose in diabetes mellitus with gastroparesis. 54 61
18946177 2009
11
Application of ghrelin to gastrointestinal diseases. 54 61
18821473 2008
12
Effects of oral mitemcinal (GM-611), erythromycin, EM-574 and cisapride on gastric emptying in conscious rhesus monkeys. 61 54
17934842 2008
13
Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis - a randomized, multicentre, placebo-controlled study. 54 61
17894654 2007
14
Potential of ghrelin as a therapeutic approach for gastrointestinal motility disorders. 61 54
17011824 2006
15
Ghrelin stimulates gastric emptying and hunger in normal-weight humans. 61 54
16772353 2006
16
Abnormal ghrelin and pancreatic polypeptide responses in gastroparesis. 54 61
16868831 2006
17
Ghrelin gastrokinetic action in patients with neurogenic gastroparesis. 61 54
16426704 2006
18
[The effects of enteral nutrition vs parenteral nutrition on gastric motility and gastroenteric hormones after subtotal gastrectomy: a perspective randomized compared clinical trial]. 54 61
16836917 2006
19
Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. 61 54
16492694 2006
20
Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. 61 54
16085693 2005
21
Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. 54 61
16225494 2005
22
Novel approaches to the treatment of nausea and vomiting. 61 54
10697661 1999
23
Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. 54 61
8299441 1993
24
Erythromycin, motilin, and gastroparesis. 61 54
1464218 1992
25
Endotracheal Intubation Using Alfentanil in a Pediatric Patient with a Mitochondrial Myopathy and Gastroparesis. 61
33552640 2021
26
Laparoscopic duodenum-preserving total pancreatic head resection using real-time indocyanine green fluorescence imaging. 61
32221750 2021
27
Teaching peroral endoscopic pyloromyotomy (POP) to practicing endoscopists: An "into-the-fire" approach to simulation. 61
33023755 2021
28
Esophageal Thermal Injury after Catheter Ablation for Atrial Fibrillation with High-Power (50 Watts) Radiofrequency Energy. 61
33525069 2021
29
Gastrointestinal motility disorders in neurologic disease. 61
33586685 2021
30
Diabetic gastroparesis: An overview of pathogenesis, clinical presentation and novel therapies, with a focus on ghrelin receptor agonists. 61
32948398 2021
31
Clinical Characterization of Pediatric Gastroparesis Using a Four-Hour Gastric Emptying Scintigraphy Standard. 61
33605658 2021
32
Practice-Changing Milestones in Anti-reflux and Hiatal Hernia Surgery: a Single Surgeon Perspective over 27 years and 1200 Operations. 61
33532979 2021
33
A case of acute pancreatitis after intrapyloric botulinum toxin injection to treat gastroparesis. 61
33579661 2021
34
Relationship of Motor Mechanisms to Gastroparesis Symptoms: Towards Individualized Treatment. 61
33566731 2021
35
Gastroparesis in the Hospital Setting. 61
33336872 2021
36
Gastric peroral endoscopic pyloromyotomy for decompensated gastroparesis: comprehensive motility analysis in relation to treatment outcomes. 61
33532550 2021
37
Gastroparesis and Severity of Delayed Gastric Emptying: Comparison of Patient Characteristics, Treatments and Medication Adverse Events. 61
32306190 2021
38
Functional dyspepsia and gastroparesis in tertiary care are interchangeable syndromes with common clinical and pathological features. 61
33548234 2021
39
Concise Commentary: Don't Delay Identifying Delayed Gastric Emptying in Gastroparesis Patients. 61
32440748 2021
40
Body weight in patients with idiopathic gastroparesis. 61
32930463 2021
41
Enteral Feeding Intolerance: Updates in Definitions and Pathophysiology. 61
33242218 2021
42
Esophageal and Gastric Motility Disorders in the Elderly. 61
33213764 2021
43
Autonomic and enteric function profiling can predict disordered gastric emptying in diabetic gastropathy. 61
33433835 2021
44
Bouveret's syndrome: a strategic approach for management. 61
33563692 2021
45
Randomized comparison of oesophageal protection with a temperature control device: results of the IMPACT study. 61
33205201 2021
46
Addition of small-bowel transit scintigraphy to gastric emptying for assessment of patients with upper gastrointestinal symptoms. 61
32996253 2021
47
Gastric Peroral Endoscopic Myotomy (GPOEM): a Helpful Tool for Post Laparoscopic Sleeve Gastrectomy Gastroparesis. 61
32524525 2021
48
Gastric Electrical Stimulation for Treatment of Refractory Gastroparesis: the Current Approach to Management. 61
33483775 2021
49
Plasma endocannabinoids and cannabimimetic fatty acid derivatives are altered in gastroparesis: A sex- and subtype-dependent observation. 61
32779297 2021
50
Prucalopride in diabetic and connective tissue disease-related gastroparesis: Randomized placebo-controlled crossover pilot trial. 61
32743954 2021

Variations for Gastroparesis

Expression for Gastroparesis

Search GEO for disease gene expression data for Gastroparesis.

Pathways for Gastroparesis

Pathways related to Gastroparesis according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.24 SST SCT MLNR MLN GIP GHSR
2 12.37 KCNH2 CYP3A4 CYP2D6 ABCB1
3
Show member pathways
12.07 SST SCT NOS1 GAST CCK ADRA1D
4 12.05 SST GIP GHSR GHRL DRD2
5
Show member pathways
11.82 CYP3A4 CYP2D6 ABCB1
6 11.65 SCT CYP3A4 ABCB1
7
Show member pathways
11.61 CYP3A4 CYP2D6 ABCB1
8
Show member pathways
11.5 CYP3A4 CYP2D6 ABCB1
9
Show member pathways
11.44 CYP3A4 CYP2D6 ABCB1
10
Show member pathways
11.32 CYP3A4 CYP2D6 ABCB1
11
Show member pathways
11.12 CYP3A4 CYP2D6 ABCB1
12
Show member pathways
11.08 CYP3A4 CYP2D6 ABCB1
13 10.81 CYP3A4 ABCB1
14
Show member pathways
10.77 CYP3A4 CYP2D6
15 10.73 CYP3A4 ABCB1
16 10.72 CYP2D6 ABCB1
17 10.71 CYP3A4 ABCB1
18 10.49 CYP3A4 ABCB1
19 10.23 TH GHSR GHRL DRD2
20 9.98 SCT GAST CCK

GO Terms for Gastroparesis

Biological processes related to Gastroparesis according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.87 TH NOS1 HMOX1 DRD2
2 memory GO:0007613 9.81 TH GIP CCK
3 response to hormone GO:0009725 9.77 NOS1 GHSR GHRL
4 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.66 DRD2 ADRA1D
5 positive regulation of cAMP-mediated signaling GO:0043950 9.66 SCT GIP
6 oxidative demethylation GO:0070989 9.65 CYP3A4 CYP2D6
7 neurotransmitter biosynthetic process GO:0042136 9.65 TH NOS1
8 response to acidic pH GO:0010447 9.65 SST GIP
9 positive regulation of growth GO:0045927 9.64 GHSR GHRL
10 synaptic transmission, dopaminergic GO:0001963 9.64 TH DRD2
11 negative regulation of appetite GO:0032099 9.63 GHSR CCK
12 response to nicotine GO:0035094 9.63 TH HMOX1 DRD2
13 response to drug GO:0042493 9.63 TH SST HMOX1 GIP DRD2 ABCB1
14 adult feeding behavior GO:0008343 9.62 GHSR GHRL
15 positive regulation of growth hormone secretion GO:0060124 9.62 GHRL DRD2
16 hyaloid vascular plexus regression GO:1990384 9.61 TH DRD2
17 heterocycle metabolic process GO:0046483 9.61 CYP3A4 CYP2D6
18 positive regulation of multicellular organism growth GO:0040018 9.61 GHSR GHRL DRD2
19 drug catabolic process GO:0042737 9.59 CYP3A4 CYP2D6
20 growth hormone secretion GO:0030252 9.58 GHSR GHRL
21 monoterpenoid metabolic process GO:0016098 9.58 CYP3A4 CYP2D6
22 negative regulation of insulin secretion GO:0046676 9.58 GHSR GHRL DRD2
23 positive regulation of eating behavior GO:1904000 9.56 GHSR GHRL
24 response to nutrient levels GO:0031667 9.56 TH SCT GIP GHRL
25 regulation of transmission of nerve impulse GO:0051969 9.55 GHSR GHRL
26 positive regulation of appetite GO:0032100 9.54 GHSR GHRL
27 regulation of gastric motility GO:1905333 9.52 GHSR GHRL
28 positive regulation of small intestine smooth muscle contraction GO:1904349 9.51 GHSR GHRL
29 exogenous drug catabolic process GO:0042738 9.5 NOS1 CYP3A4 CYP2D6
30 isoquinoline alkaloid metabolic process GO:0033076 9.49 TH CYP2D6
31 alkaloid catabolic process GO:0009822 9.48 CYP3A4 CYP2D6
32 positive regulation of small intestinal transit GO:0120058 9.37 GHSR GHRL
33 G protein-coupled receptor signaling pathway GO:0007186 9.36 SST SCT MLNR MLN GIP GHSR
34 postsynaptic modulation of chemical synaptic transmission GO:0099170 9.13 GHSR GHRL DRD2

Molecular functions related to Gastroparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.77 TH NOS1 HMOX1 CYP3A4 CYP2D6
2 monooxygenase activity GO:0004497 9.5 TH CYP3A4 CYP2D6
3 hormone binding GO:0042562 9.4 MLNR GHSR
4 dopamine binding GO:0035240 9.26 TH DRD2
5 heme binding GO:0020037 9.26 NOS1 HMOX1 CYP3A4 CYP2D6
6 hormone activity GO:0005179 9.17 SST SCT MLN GIP GHRL GAST
7 tetrahydrobiopterin binding GO:0034617 9.16 TH NOS1

Sources for Gastroparesis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....